Biogen (BIIB) Q4 2024 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Mike McDonnell Incoming Chief Financial Officer — Robin Kramer Head of Development — Priya Singhal Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Total revenue -- $2.5 billion for the quarter, representing 3% growth compared to the fourth quarter of 2023. Full-year revenue -- $9.7 billion, a 2% decline from 2023, aligning with guidance of a low single-digit decrease. Non-GAAP diluted EPS -- $3.44 for the quarter, up 17% from the fourth quarter of 2023; $16.47 for the full year, a 12% increase versus 2023. Free cash flow -- $722 million for the quarter and $2.7 billion for the full year; yearly free cash flow improved by $1.4 billion from 2023. Multiple sclerosis (MS) product revenue -- Declined roughly 8% at actual currency and 9% at constant currency compared to the fourth quarter of 2023 due to increased competition, offset by some seasonal channel dynamics. Rare disease franchise revenue -- $535 million for the qu
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Agios (AGIO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire
- Royalty Pharma (RPRX) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
- Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Declares Second Quarter 2026 Dividend [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 4/13/26 - Form 8-K
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- RPRX's page on the SEC website